These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27554587)

  • 1. Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment?
    Prucha M; Zazula R; Russwurm S
    Arch Immunol Ther Exp (Warsz); 2017 Feb; 65(1):37-49. PubMed ID: 27554587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized medicine with IgGAM compared with standard of care for treatment of peritonitis after infectious source control (the PEPPER trial): study protocol for a randomized controlled trial.
    Kalvelage C; Zacharowski K; Bauhofer A; Gockel U; Adamzik M; Nierhaus A; Kujath P; Eckmann C; Pletz MW; Bracht H; Simon TP; Winkler M; Kindgen-Milles D; Albertsmeier M; Weigand M; Ellger B; Ragaller M; Ullrich R; Marx G
    Trials; 2019 Mar; 20(1):156. PubMed ID: 30832742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards personalized medicine: a scoping review of immunotherapy in sepsis.
    Slim MA; van Mourik N; Bakkerus L; Fuller K; Acharya L; Giannidis T; Dionne JC; Oczkowski SJW; Netea MG; Pickkers P; Giamarellos-Bourboulis EJ; Müller MCA; van der Poll T; Wiersinga WJ; ; Vlaar APJ; van Vught LA
    Crit Care; 2024 May; 28(1):183. PubMed ID: 38807151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sepsis immunopathology: perspectives of monitoring and modulation of the immune disturbances.
    Skirecki T; Borkowska-Zielińska U; Złotorowicz M; Hoser G
    Arch Immunol Ther Exp (Warsz); 2012 Apr; 60(2):123-35. PubMed ID: 22301668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision Immunotherapy for Sepsis.
    Peters van Ton AM; Kox M; Abdo WF; Pickkers P
    Front Immunol; 2018; 9():1926. PubMed ID: 30233566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in sepsis - brake or accelerate?
    Steinhagen F; Schmidt SV; Schewe JC; Peukert K; Klinman DM; Bode C
    Pharmacol Ther; 2020 Apr; 208():107476. PubMed ID: 31931100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.
    Patil NK; Bohannon JK; Sherwood ER
    Pharmacol Res; 2016 Sep; 111():688-702. PubMed ID: 27468649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of sepsis.
    van der Poll T
    Lancet Infect Dis; 2001 Oct; 1(3):165-74. PubMed ID: 11871493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sepsis: time has come to focus on the later stages.
    Schefold JC; Hasper D; Volk HD; Reinke P
    Med Hypotheses; 2008 Aug; 71(2):203-8. PubMed ID: 18448264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Balance between Hyperinflammation and Immunosuppression in Sepsis.
    Yadav H; Cartin-Ceba R
    Semin Respir Crit Care Med; 2016 Feb; 37(1):42-50. PubMed ID: 26820273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?
    Boomer JS; Green JM; Hotchkiss RS
    Virulence; 2014 Jan; 5(1):45-56. PubMed ID: 24067565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advances in immunotherapeutic research of sepsis].
    Dong L; Lyu J; Ding L; Liu Z
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Feb; 29(2):184-187. PubMed ID: 28625271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staging and Personalized Intervention for Infection and Sepsis.
    Beckmann N; Salyer CE; Crisologo PA; Nomellini V; Caldwell CC
    Surg Infect (Larchmt); 2020 Nov; 21(9):732-744. PubMed ID: 32240042
    [No Abstract]   [Full Text] [Related]  

  • 14. The beginning of personalized medicine in sepsis: small steps to a bright future.
    Christaki E; Giamarellos-Bourboulis EJ
    Clin Genet; 2014 Jul; 86(1):56-61. PubMed ID: 24579691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the therapy for sepsis in children.
    Anderson MR; Blumer JL
    Pediatr Clin North Am; 1997 Feb; 44(1):179-205. PubMed ID: 9057790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change?
    Leentjens J; Kox M; van der Hoeven JG; Netea MG; Pickkers P
    Am J Respir Crit Care Med; 2013 Jun; 187(12):1287-93. PubMed ID: 23590272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sepsis biomarkers.
    Prucha M; Bellingan G; Zazula R
    Clin Chim Acta; 2015 Feb; 440():97-103. PubMed ID: 25447700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of sepsis: current status of clinical immunotherapy.
    O'Callaghan A; Redmond HP
    Surgeon; 2006 Dec; 4(6):355-61. PubMed ID: 17152200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cytokine inhibitors in intensive care].
    Villard J; Jolliet P; Chevrolet JC
    Rev Mal Respir; 1995; 12(4):335-42. PubMed ID: 7481045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.